Financial Performance Highlights (FY26)

The company reported a significant turnaround and growth in FY26 financial performance:

  • Total Revenue: ₹103.96 Crore, representing a 160% year-on-year increase from ₹40.04 Crore in FY25
  • Profit After Tax: ₹5.94 Crore, showing a 240% year-on-year increase from ₹1.75 Crore in FY25
  • Reserves: ₹3.72 Crore, turning positive from negative reserves of ₹-2.20 Crore in FY25
  • Segment Result: ₹5.54 Crore (profit before tax and other items)

Segment-wise Performance Breakdown

Financial Inclusion & Digital Services Division

  • Revenue: ₹40.72 Crore (39% of total revenue)
  • Segment Result: ₹0.86 Crore profit
  • Growth: 7.7% year-on-year from ₹37.79 Crore in FY25
  • Operations: Services 5,000 villages across 10 states with access to ~40 million rural population
  • Partnerships: Works with 7 Public & Regional Rural Banks

Agri Supply Chain & Technologies Division

  • Revenue: ₹60.69 Crore (58% of total revenue)
  • Segment Result: ₹4.71 Crore profit
  • This is a new vertical that did not exist in FY25
  • Business includes Agri Commerce & Trade Finance, Smart Retail & Crop Advisory

Diagnostics & Healthcare Division

  • Revenue: Not yet contributing (early stage)
  • Segment Result: Not specified
  • Strategic partnership with Huwel Lifesciences for molecular diagnostics

Other Segments

  • Revenue: ₹2.55 Crore (3% of total revenue)
  • Segment Result: ₹(0.03) Crore loss
  • Growth: 13.7% year-on-year from ₹2.24 Crore in FY25

Strategic Priorities and Future Outlook

Agri Tech Segment Goals (Next 3 Years)

  • Digitally onboard 20 million farmers from the current service base of 40 million farmers
  • Open 1,000 smart agri-stores for agri-input retail and agri-output aggregation
  • Facilitate transactions with GMV of USD 1 Billion through rural commerce, sale of agri-inputs and market access for produced commodities
  • Note: These goals are subject to market conditions and regulatory approvals

Health Tech Segment Strategy

  • Strategic partnership with Huwel Lifesciences to build a scalable molecular diagnostics platform
  • Huwel Lifesciences has 140+ molecular diagnostic products covering TB, HPV, Hepatitis, Sepsis, AMR, Respiratory & Infectious Diseases
  • Technology features include Point-of-Care Testing (results in 15-30 minutes), affordable and scalable open RT-PCR architecture, and end-to-end Made in India development
  • Supported by Gates Foundation and aligned with WHO-led disease elimination programs

Business Model Overview

The company operates as a diversified platform company across three divisions:

1. Financial Inclusion & Digital Services - Banking services in rural areas

2. Agri Supply Chain & Technologies - Agri commerce and retail

3. Diagnostics & Healthcare - Molecular diagnostics through partnership